CLSA Recognizes Three State Legislators as Life Sciences Champions And Welcomes New Board Members
President & CEO
CLSA – California Life Sciences Association
February 25, 2017
Welcoming New Members
Please welcome the 23 new CLSA members who joined us in the last month: Basepaws, British Consulate-General of San Francisco, Bruce Quinn Associates LLC, Checkerspot, Corealis Pharma, E&B Technologies/Trefoil, Exinda Therapeutics, Facile Therapeutics, InhibRrx, Mekonos, mFluiDx Inc., Microsynbiotix LLC, Microtek, NewOpp Biopharmaceuticals, Nucleus Biologics, Nuredis Inc., Resilience Industries Inc., Sciogen LLC, Solvexa LLC, Somatek Inc., Stroma Medical, VeriSkin Inc., and Wild Type Inc. Our membership portfolio grows ever more robust with the addition of these organizations which add significantly to the expertise and resources available in the CLSA network.
CLSA Recognizes Three Legislative Life Sciences Champions
At CLSA’s Back to Session Reception and Board Dinner on February 7th, I was very pleased to be able to present CLSA’s 2016 Life Sciences Champion awards to Senators Richard Pan (D-Sacramento) and Janet Nguyen (R – Garden Grove) and Assemblywoman Lorena Gonzales Fletcher (D-San Diego) in acknowledgement of their thoughtful leadership and resolute efforts towards advancing biotechnology, biomedical science, pharmaceutical and medical device innovation in California during the past year.
CLSA Welcomes New Directors to The Board
We were all pleased to welcome two exciting new Board members to the CLSA Board of Directors this month:
Larry W. Kwak, MD, PhD, Vice President and Associate Cancer Center Director of Translational Research at City of Hope. Passionate about harnessing the body’s immune system to battle cancer, Dr. Kwak’s interest in the field was sparked by a high school mentor and has continued for nearly three decades. He takes special pride in his ability to rapidly translate basic research into human clinical trials, and was Named one of Time Magazine’s 100 Most Influential People in 2010.
Daria Mochly-Rosen, PhD, Founder and Co-Director, SPARK Translational Research Program and Professor, Chemical and Systems Biology at Stanford University School of Medicine. She leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop several drug leads for human diseases with interest in mitochondrial biology and pathology.
It’s Not Too Late – Join Us for CLSA’s Power Partnering Days
Are you an emerging company looking to partner with a global life sciences organization? If you haven’t already applied, check out our back-to-back March Partnering Days with Bay Area power players, AbbVie and Merck! CLSA’s Partnering Days offer targeted one-on-one meetings that create co-development opportunities. Application is required for one-on-one meetings – if interested, please apply for a private 45-minute meeting:
|Merck Partnering Day: Friday, March 17, 2017|
|AbbVie Partnering Day: Tuesday, March 28, 2017|
CLSA Congratulates OncoCyte for “Buzz of BIO” Win at 2017 BIO CEO & Investor Conference
We’d like to highlight CLSA member OncoCyte’s win for “Buzz of BIO” in the Diagnostics and Beyond category at the 2017 BIO CEO & Investor Conference in New York this month. They were selected because of their groundbreaking work in cancer confirmatory diagnostics that can help physicians better manage lung nodules to prevent avoidable procedures and reduce the overall cost of lung cancer screening. Congratulations to CLSA Board member Bill Arnett and the entire OncoCyte team!
CLSI Announces Spring 2017 FAST Companies
CLSI is excited to announce the Spring 2017 FAST companies: Encellin, Facile Therapeutics, Hepatx, LogicInk, Microsynbiotix, and X-Therma. After 12 weeks of advising from a team of industry experts, the Spring cohort will present at the Spring 2017 FAST Closing Showcase & Celebration at UCSF Byers Auditorium on June 13, 2017.
CLSA Highlights Rare Disease Day and Heart Health Month
This month, CLSA spotlights the important work our members, partners, and team are doing to develop and advance rare disease treatment and heart health.
More than 70 countries will observe Tuesday, February 28th as Rare Disease Day to bring greater attention to the fact that rare diseases strike families in heartbreaking ways: an average patient will see 8 physicians, be misdiagnosed 3 times, and endure a 7-plus year wait before receiving a correct diagnosis. Global Genes created this infographic to raise awareness for the impact of rare diseases around the globe. At CLSA, many of our member organizations tackle rare diseases with their research and treatments, and we are committed to representing their voice and ensuring that their impact continues to grow. On Rare Disease Day, February 28th, I plan to participate in a panel at the Rare Disease Legislative Advocates (RDLA) 2017 Legislative Conference in Washington, DC.
We also recognize the importance of Heart Health Month in February. Heart disease is the leading cause of death for both men and women in the United States. The good news? It is also one of the most preventable. Friday, February 3rd was Heart Health Day, so our CLSA team members in Sacramento, San Francisco, San Diego, and Washington DC wore red to help increase awareness of heart disease. We’d also like to recognize our new Board Chair, Don Bobo, and Edwards Life Sciences for their life-saving efforts to create patient-focused treatments for structural heart disease.
President & CEO
California Life Sciences Association
PS – Have newsworthy items to submit for consideration for our monthly CLSA Bulletin? Feel free to send those tips to Bianca Leveriza, CLSA’s Manager, Marketing & Programs (BLeveriza@CALifeSciences.org).